JOCHEN H LORCH M.D. NPI 1518913094

NPI Information

  • NPI: 1518913094
  • Provider Name: JOCHEN H LORCH, M.D.
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 676 N SAINT CLAIR ST STE 850
    CHICAGO, IL
    ZIP 60611
  • Phone: (312) 695-6180

Map and Directions

Get Directions

NPI Details

Jochen H Lorch, M.D. is a hematology and oncology internal medicine in Chicago, IL with 32 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Jochen H Lorch, M.D. NPI is 1518913094. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

676 N SAINT CLAIR ST STE 850
CHICAGO, IL
ZIP 60611-124
Phone: (312) 695-6180
Fax: (312) 695-6189

The NPI 1518913094 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, nivolumab, 1 mg (HCPCS:J9299)
  • Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, carfilzomib, 1 mg (HCPCS:J9047)
  • Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
  • Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
  • Unclassified drugs (HCPCS:J3490)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
  • Application of on-body injector for under skin injection (HCPCS:96377)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Diagnostic exam of voice box using a flexible endoscope (HCPCS:31575)

The enumeration date for this NPI number is 5/26/2006 and was last updated on 10/29/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0003XInternal MedicineHematology & Oncology224308MASSACHUSETTSNo
2207RH0003XInternal MedicineHematology & Oncology036100716ILLINOISYes

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.